Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 12, 2025World Journal of Gastrointestinal Oncology

Targeting SHP2: Dual breakthroughs in colorectal cancer therapy–from signaling pathway modulation to immune microenvironment remodeling

View Full Paper
Ask AI
Bookmark
Share

Authors

PLPan LiuJCJia Chen

Discussion

Loading...

Member takes

Overview

Targeting SHP2 shows promise in colorectal cancer by regulating signaling pathways and reshaping the tumor microenvironment.

Key Points

  • SHP2 is an oncogenic tyrosine phosphatase linked to colorectal cancer progression.
  • Targeting SHP2 affects signaling pathways like RAS/ERK and alters immune responses in the tumor microenvironment.
  • Clinical trials are underway for SHP2 inhibitors, both alone and in combination therapies.
  • Targeting SHP2 could enhance precision oncology in colorectal cancer treatments.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/689a02afe6551bb0af8cbeb6https://doi.org/10.4251/wjgo.v17.i7.107380
View Full Paper
Ask AI
Bookmark
Share